| ISIN | LU2050612402 |
|---|---|
| Valor Number | |
| Bloomberg Global ID | |
| Fund Name | JPMorgan Funds – Thematics - Genetic Therapies A (acc)-USD |
| Fund Provider |
J.P. Morgan Bank Luxembourg S.A.
6, route de Trèves L-2633, Senningerberg Grand Duchy of Luxembourg |
| Fund Provider | J.P. Morgan Bank Luxembourg S.A. |
| Representative in Switzerland |
JPMorgan Asset Management (Switzerland) LLC Genève Phone: +41 22 744 11 11 |
| Distributor(s) |
JP Morgan Asset Management (Europe) Sàrl Senningerberg Phone: +352 34 10 1 |
| Asset Class | Equities |
| EFC Category | |
| Distribution Policy | Accumulation |
| Home Country | Luxembourg |
| Issuing Condition | Combination of issuing commission charged by the fund management company and transaction fee charged by the fund |
| Redemption Condition | Combination of redemption commission charged by the fund management company and transaction fee charged by the fund |
| Investment Strategy *** | To achieve a return by investing in companies with exposure to the theme of genetic therapies, globally. |
| Peculiarities |
| Current Price * | 111.72 USD | 11.12.2025 |
|---|---|---|
| Previous Price * | 110.90 USD | 10.12.2025 |
| 52 Week High * | 112.11 USD | 08.12.2025 |
| 52 Week Low * | 72.17 USD | 09.04.2025 |
| NAV * | 111.72 USD | 11.12.2025 |
| Issue Price * | ||
| Redemption Price * | ||
| Closing Price * | ||
| Indicative Minimum Price | ||
| Fund Assets *** | 411,426,081 | |
| Unit/Share Assets *** | 109,612,251 | |
| Trading Information SIX | ||
| YTD Performance | +23.90% |
31.12.2024 - 11.12.2025
31.12.2024 11.12.2025 |
|---|---|---|
| YTD Performance (in CHF) | +9.20% |
31.12.2024 - 11.12.2025
31.12.2024 11.12.2025 |
| 1 month | +8.67% |
11.11.2025 - 11.12.2025
11.11.2025 11.12.2025 |
| 3 months | +18.33% |
11.09.2025 - 11.12.2025
11.09.2025 11.12.2025 |
| 6 months | +29.22% |
11.06.2025 - 11.12.2025
11.06.2025 11.12.2025 |
| 1 year | +15.22% |
11.12.2024 - 11.12.2025
11.12.2024 11.12.2025 |
| 2 years | +21.20% |
11.12.2023 - 11.12.2025
11.12.2023 11.12.2025 |
| 3 years | +2.45% |
12.12.2022 - 11.12.2025
12.12.2022 11.12.2025 |
| 5 years | -35.60% |
11.12.2020 - 11.12.2025
11.12.2020 11.12.2025 |
| Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI Date | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Avidity Biosciences Inc Ordinary Shares | 3.76% | |
|---|---|---|
| uniQure NV | 3.44% | |
| Ionis Pharmaceuticals Inc | 3.35% | |
| PTC Therapeutics Inc | 3.27% | |
| CRISPR Therapeutics AG | 2.99% | |
| Gilead Sciences Inc | 2.82% | |
| Novartis AG Registered Shares | 2.78% | |
| Alnylam Pharmaceuticals Inc | 2.78% | |
| Krystal Biotech Inc | 2.77% | |
| Wuxi AppTec Co Ltd | 2.66% | |
| Last data update | 31.10.2025 | |
| TER *** | 0.95% |
|---|---|
| TER date *** | 30.06.2025 |
| Performance Fee *** | |
| PTR | |
| Max. Management Fee *** | 0.72% |
| Ongoing Charges *** | 0.95% |
|
SRRI ***
|
|
| SRRI date *** | 30.11.2025 |